All News

Found 11,786 articles

• Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

  5/4/2023

  Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors reported financial results and business highlights for the first quarter ended March 31, 2023.

• Three Finalists Announced for the 2023 Bloom Burton Award

  5/4/2023

  Bloom Burton & Co. is pleased to announce the finalists for the 2023 Bloom Burton Award.

• 

  GSK Wins First-Ever FDA Approval for an RSV Vaccine

  5/3/2023

  The regulatory decision marks a turning point in the RSV race in what’s expected to be a competitive space.

• FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine

  5/3/2023

  Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States.

• Small Molecule Drug Discovery Market ($50.82Bn by 2027) Driven by Rare Diseases Segment | The Insight Partners

  5/3/2023

  The Insight Partners published latest research report on "Small Molecule Drug Discovery Market Size Report, Share, Growth & Trends Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapeutic Area; Process/Phase; and Geography”,

• Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer

  5/2/2023

  Amphista Therapeutics announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer.

• 

  Astellas to Buy Iveric Bio for $5.9B in Age-Related Blindness Play

  5/1/2023

  Japanese biopharma scoops up Iveric’s investigational drug for age-related blindness disease. The drug, which trails Apellis’ Syfovre, is awaiting FDA approval with a decision expected by August.

• Galera Expands Commercial Leadership Team

  5/1/2023

  Galera Therapeutics, Inc. today announced the appointment of accomplished pharmaceutical sales, market access, and commercial operations executives to Galera’s senior commercial leadership team, effective immediately.

• Gene Bio Medical Announces Partnership with Prairie Hub for Pandemic Preparedness

  4/28/2023

  Gene Biotechnology Enterprises Ltd, doing business as Gene Bio Medical, is proud to announce its partnership with the Prairie Hub for Pandemic Preparedness as a key commercialization partner.

• A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the US

  4/27/2023

  A new antidepressant drug candidate being developed by researchers at Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) is said to have mechanistic activity and therapeutic features that set it apart from almost all of the currently approved antidepressants in the U.S.

• At 4% CAGR, Antibiotics Market to Reach $59.25 Billion, Globally, by 2028 – The Insight Partners

  4/27/2023

  The Insight Partners published latest research report on "Antibiotics Market Share Report, Size, Trends, Growth & Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class; Action Mechanism, and Geography" the global market size was valued at USD 44,111.31 million in 2020 and is projected to reach USD 59,253.24 million in 2028; it is expected to grow at a CAGR of 4% during 2021–2028.

• Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including at the 2023 ASCO Annual Meeting

  4/26/2023

  Zentalis ® Pharmaceuticals, Inc. announced today that it will present positive clinical data from its Phase 1b trial investigating azenosertib in combination with chemotherapy in patients with advanced platinum-resistant ovarian cancer in a poster at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, June 2-6, 2023.

• VBI Vaccines Appoints Vaughn Himes to Board of Directors

  4/25/2023

  VBI Vaccines Inc. today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of Directors.

• GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry

  4/24/2023

  GRI Bio, Inc. today announced the appointments of David Szekeres, Roelof Rongen, MSE, MBA, and Camilla V. Simpson, M.Sc. to the Company’s Board of Directors.

• Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

  4/20/2023

  Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta.

• Respiratory Inhalers Market to Grow at 5.7% CAGR to Reach $43.44Bn by 2028 - The Insight Partners

  4/20/2023

  The Insight Partners published latest research report on "Respiratory Inhalers Market Size Report, Share, Trends, Growth and Revenue Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, and Disease Indication" the global market size is expected to grow from USD 31,144.56 million in 2022 to USD 43,446.19 million by 2028; it is estimated to record a CAGR of 5.7% from 2022 to 2028.

• Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023

  4/18/2023

  Surface Oncology today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.

• ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

  4/17/2023

  ReCode Therapeutics announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.

• Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023

  4/17/2023

  ZentalisTM Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announces preclinical data that supports CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib, the Company’s potentially first-in-class Wee1 inhibitor product candidate.

• Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources

  4/13/2023

  Jasper Therapeutics, Inc. announced the appointment of Matthew Ford as the Company’s Vice President, Human Resources.